[go: up one dir, main page]

WO1998023759A3 - Identification of inhibitors that prevent access of telomerase to chromosomal terminus - Google Patents

Identification of inhibitors that prevent access of telomerase to chromosomal terminus Download PDF

Info

Publication number
WO1998023759A3
WO1998023759A3 PCT/US1997/021272 US9721272W WO9823759A3 WO 1998023759 A3 WO1998023759 A3 WO 1998023759A3 US 9721272 W US9721272 W US 9721272W WO 9823759 A3 WO9823759 A3 WO 9823759A3
Authority
WO
WIPO (PCT)
Prior art keywords
telomerase
identification
inhibitors
prevent access
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/021272
Other languages
French (fr)
Other versions
WO1998023759A2 (en
WO1998023759A9 (en
Inventor
Victoria Lundblad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Priority to EP97953039A priority Critical patent/EP0942991A2/en
Priority to JP52474398A priority patent/JP2001507570A/en
Priority to AU56868/98A priority patent/AU5686898A/en
Priority to CA002272989A priority patent/CA2272989A1/en
Publication of WO1998023759A2 publication Critical patent/WO1998023759A2/en
Publication of WO1998023759A9 publication Critical patent/WO1998023759A9/en
Publication of WO1998023759A3 publication Critical patent/WO1998023759A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention discloses novel telomerase-associated proteins as well as methods for isolating the genes encoding telomerase-associated proteins. Using novel screening methods presented additional telomerase-associated genes may be isolated and their protein products expressed and characterized. Identification of protein-protein interactions required for the in vivo function of telomerase provides the basis for a novel screening method for anti-tumor agents.
PCT/US1997/021272 1996-11-26 1997-11-26 Identification of inhibitors that prevent access of telomerase to chromosomal terminus Ceased WO1998023759A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP97953039A EP0942991A2 (en) 1996-11-26 1997-11-26 Identification of inhibitors that prevent access of telomerase to chromosomal terminus
JP52474398A JP2001507570A (en) 1996-11-26 1997-11-26 Identification of inhibitors that inhibit telomerase access to chromosomal ends
AU56868/98A AU5686898A (en) 1996-11-26 1997-11-26 Identification of inhibitors that prevent access of telomerase to chrom osomal terminus
CA002272989A CA2272989A1 (en) 1996-11-26 1997-11-26 Identification of inhibitors that prevent access of telomerase to chromosomal terminus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75669396A 1996-11-26 1996-11-26
US08/756,693 1996-11-26

Publications (3)

Publication Number Publication Date
WO1998023759A2 WO1998023759A2 (en) 1998-06-04
WO1998023759A9 WO1998023759A9 (en) 1998-09-17
WO1998023759A3 true WO1998023759A3 (en) 1998-12-17

Family

ID=25044649

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/021272 Ceased WO1998023759A2 (en) 1996-11-26 1997-11-26 Identification of inhibitors that prevent access of telomerase to chromosomal terminus

Country Status (6)

Country Link
EP (1) EP0942991A2 (en)
JP (1) JP2001507570A (en)
KR (1) KR20000057258A (en)
AU (1) AU5686898A (en)
CA (1) CA2272989A1 (en)
WO (1) WO1998023759A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12428678B2 (en) 2016-07-01 2025-09-30 Carlsberg A/S Method to screen for a mutant within a population of organisms by applying a pooling and splitting approach

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
BR9711844A (en) 1996-10-01 2000-01-18 Geron Corp Preparation of isolated protein, substantially pure or recombinant, isolated trt protein, substantially pure or recombinant isolated trt protein, substantially pure or recombinant, isolated trt protein or a variant thereof, or a fragment, polynucleotide, synthetic, substantially pure or recombinant, isolated nucleic acid, encoding a trt protein, expression vector, transfected cell, non-human animal, or its progeny, transgenic non-human animal, antibody or its binding fragment, antibody, specifically immunoreactive under immunologically reactive conditions, for a trt protein or its immunogenic fragment, processes of determining whether a compound or treatment is a modulator of a trt activity or expression, of determining whether a test compound is a modulator of a trt activity, of preparing recombinant telomerase, to detect a trt gene product in a sample, to detect the presence of d and at least one telomerase positive human cell in a biological sample comprising human cells, to diagnose a telomerase-related condition in a mammal, to increase the proliferative ability of a vertebrate cell in vitro, to detect the presence of a sequence of polynucleotide encoding at least a part of a trt in a biological sample, to produce a polynucleotide, to detect the expression or presence of a trt in a biological sample, uses of an ampolinucleotide, an agent that increases the expression or activity of a trt, an inhibitor of the expression or telomerase activity of a protein, variant or fragment, pharmaceutical composition, substantially purified polypeptide, isolated polynucleotide sequence, telomerase complex, composition, substantially pure telomerase, isolated trt polypeptide, isolated nucleic acid.
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US6808880B2 (en) 1996-10-01 2004-10-26 Geron Corporation Method for detecting polynucleotides encoding telomerase
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
JP2002509716A (en) 1998-03-31 2002-04-02 ユニバーシティ テクノロジー コーポレイション Methods and compositions for raising an immune response to a telomerase antigen
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
KR20010096991A (en) * 2000-04-19 2001-11-08 임정빈 WT1 fragment specifically binding telomerase promoter, the gene, the expression vector and method for inhibiting cell growth by the fragment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012811A2 (en) * 1994-10-20 1996-05-02 Arch Development Corporation Yeast telomerase components and methods using them
WO1998014592A2 (en) * 1996-10-01 1998-04-09 Geron Corporation Telomerase reverse transcriptase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012811A2 (en) * 1994-10-20 1996-05-02 Arch Development Corporation Yeast telomerase components and methods using them
WO1998014592A2 (en) * 1996-10-01 1998-04-09 Geron Corporation Telomerase reverse transcriptase

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BERGER S.L. & KIMMEL A.R., EDS: "Guide to molecular cloning techniques", 1987, ACADEMIC PRESS, SAN DIEGO, USA, XP002071178 *
DATABASE EMBL SEQUENCES EMBL, Heidelberg, FRG; 1 November 1996 (1996-11-01), JOHNSTON M. ET AL.: "Chromosome XII cosmid 8543", XP002071416 *
DATABASE EMBL SEQUENCES EMBL, Heidelberg, FRG; 30 January 1995 (1995-01-30), ZEHNER J.E. & PRINGLE J.R.: "S. cerevisiae BUD6 gene", XP002071417 *
GLOVER D.M. & HAMES B.D., EDS.: "DNA cloning 2, a practical approach: Expression Systems", 1995, OXFORD UNIVERSITY PRESS, OXFORD, UK, XP002071179 *
LINGNER J. ET AL.: "Three Ever Shorter Telomere (EST) genes are dispensable for in vitro yeast telomerase activity", PROC. NATL. ACAD. SCI. USA, vol. 94, - October 1997 (1997-10-01), pages 11190 - 11195, XP002071046 *
LUNDBLAD V. & SZOSTAK J.W.: "A mutant with a defect in telomere elongation leads to secescence in yeast", CELL, vol. 57, 19 May 1989 (1989-05-19), pages 633 - 643, XP002071176 *
NUGENT C.I. ET AL.: "Cdc13p: a single-strand telomeric binding protein with a dual role in yeast telomere maintenance", SCIENCE, vol. 274, 11 October 1996 (1996-10-11), pages 249 - 252, XP002071050 *
STRATAGENE CATALOG 1995: "Two-hybrid vectors", p34 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12428678B2 (en) 2016-07-01 2025-09-30 Carlsberg A/S Method to screen for a mutant within a population of organisms by applying a pooling and splitting approach

Also Published As

Publication number Publication date
CA2272989A1 (en) 1998-06-04
JP2001507570A (en) 2001-06-12
WO1998023759A2 (en) 1998-06-04
KR20000057258A (en) 2000-09-15
EP0942991A2 (en) 1999-09-22
AU5686898A (en) 1998-06-22

Similar Documents

Publication Publication Date Title
WO1998013502A3 (en) Method to identify compounds for disrupting protein/protein interactions
CA2258502A1 (en) Modified factor viii
WO2001079459A3 (en) Polypeptides having haloperoxidase activity
ZA9711239B (en) OB fusion protein compositions and methods.
AU6411698A (en) Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
BG103977A (en) Low molecular rotamase enzymic activity inhibitors
WO1998023759A3 (en) Identification of inhibitors that prevent access of telomerase to chromosomal terminus
WO2003016475A3 (en) Nucleic acid and amino acid sequences involved in pain
HUP9900422A3 (en) Novel protein and methods for the production of the same
AU5324996A (en) Protein kinase c inhibitors
WO2000001823A3 (en) Flt3-l mutants and methods of use
AU5440198A (en) Method for the identification of peptides that recognize specific dna sequences
AU3199595A (en) Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same
AU5551299A (en) Method of identifying proteins
ZA9610285B (en) Constructs and methods for enhancing protein levels in photosynthetic organisms.
AU2585297A (en) Methods of commercial production and extraction of protein from seed
AU6833996A (en) Identification of bases in nucleic acid sequences
WO2001009384A3 (en) Serial analysis of genetic alterations
WO2000040757A3 (en) Method of identifying nucleic acids
AU2002302640A1 (en) Mutants of igf binding proteins and methods of production of antagonists thereof
AU2710400A (en) Monocyte-derived nucleic acids and related compositions and methods
WO2001004354A3 (en) Use of ras inhibitors of inhibiting muscle atrophy
ZA969617B (en) Method and agents for inhibiting protein aging.
IL140969A0 (en) Methods of identification of modulators of protein function
AU9127898A (en) Compositions and methods for the identification and quantitation of deletion sequence oligonucleotides in synthetic oligonucleotide preparations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/18-18/18, DRAWINGS, REPLACED BY NEW PAGES 1/18-18/18; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

CFP Corrected version of a pamphlet front page

Free format text: ADD INID NUMBER (63) "RELATED BY CONTINUATION (CON) OR CONTINUATION-IN-PART (CIP) TO EARLIER APPLICATION" WHICH WAS INADVERTENTLY OMITTED FROM THE FRONT PAGE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR MX US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2272989

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1998 524743

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/004853

Country of ref document: MX

Ref document number: 09308699

Country of ref document: US

Ref document number: 1019997004646

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 56868/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1997953039

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997953039

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997004646

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997953039

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019997004646

Country of ref document: KR